论文部分内容阅读
依美斯汀 (ｅｍｅｄａｓｔｉｎｅ)双富马酸盐是新的第二代Ｈ1受体拮抗剂 ,通过人体体外实验已知它能被ＣＹＰ 1Ａ2 ,ＣＹＰ 2Ｅ1和ＣＹＰ 3Ａ4代谢。这种多代谢途径使它与抗真菌药合用时不会产生心血管副作用。为了评价依美斯汀双富马酸盐与酮康唑合用的药效学和药代动力学的相
Emedastine bis-fumarate is a new second-generation H1 receptor antagonist which is known to be metabolized by CYP 1A2, CYP 2E1 and CYP 3A4 in human in vitro experiments. This multi-metabolic pathway does not cause cardiovascular side effects when combined with antifungal drugs. In order to evaluate the pharmacodynamic and pharmacokinetic profile of emamelin bisfumarate in combination with ketoconazole